These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 12824095)
41. Use of dose modification schedules is effective for blinding trials of warfarin: evidence from the WASID study. Hertzberg V; Chimowitz M; Lynn M; Chester C; Asbury W; Cotsonis G Clin Trials; 2008; 5(1):23-30. PubMed ID: 18283076 [TBL] [Abstract][Full Text] [Related]
42. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Petitti DB Ann Epidemiol; 1994 Mar; 4(2):115-8. PubMed ID: 8205277 [TBL] [Abstract][Full Text] [Related]
43. Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. Meade TW Am J Cardiol; 1990 Feb; 65(6):7C-11C. PubMed ID: 2405628 [TBL] [Abstract][Full Text] [Related]
44. Two-stage adaptive design for clinical trials with survival data. Li G; Shih WJ; Wang Y J Biopharm Stat; 2005; 15(4):707-18. PubMed ID: 16022174 [TBL] [Abstract][Full Text] [Related]
45. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Meade TW; Wilkes HC; Stirling Y; Brennan PJ; Kelleher C; Browne W Eur Heart J; 1988 Aug; 9(8):836-43. PubMed ID: 3053176 [TBL] [Abstract][Full Text] [Related]
46. A visual medication schedule to improve anticoagulation control: a randomized, controlled trial. Machtinger EL; Wang F; Chen LL; Rodriguez M; Wu S; Schillinger D Jt Comm J Qual Patient Saf; 2007 Oct; 33(10):625-35. PubMed ID: 18030865 [TBL] [Abstract][Full Text] [Related]
48. A randomized trial of an intervention to improve use and adherence to effective coronary heart disease prevention strategies. Sheridan SL; Draeger LB; Pignone MP; Keyserling TC; Simpson RJ; Rimer B; Bangdiwala SI; Cai J; Gizlice Z BMC Health Serv Res; 2011 Dec; 11():331. PubMed ID: 22141447 [TBL] [Abstract][Full Text] [Related]
49. Hypothesis: polypharmacy. The treatment of thrombotic risk. O'Brien JR Haematologica; 1980 Aug; 65(4):542-5. PubMed ID: 6774929 [No Abstract] [Full Text] [Related]
50. Aspirin under fire: aspirin use in the primary prevention of coronary heart disease. Miller MG; Lucas BD; Papademetriou V; Elhabyan AK Pharmacotherapy; 2005 Jun; 25(6):847-61. PubMed ID: 15927904 [TBL] [Abstract][Full Text] [Related]
51. Patient 'buy-in' and prevention. Mazza D Aust Fam Physician; 2010 Jul; 39(7):453-4. PubMed ID: 20628655 [TBL] [Abstract][Full Text] [Related]
52. Effect of factor VII genotype on response to warfarin treatment. Lane A; Green F; Humphries S; Ruddock V; Meade T Thromb Haemost; 1995 Feb; 73(2):325. PubMed ID: 7792751 [No Abstract] [Full Text] [Related]
53. [Aspirin in the primary prevention of the hypertensive patient]. Barrios Alonso V; Campuzano Ruiz R Rev Clin Esp; 2002 Dec; 202(12):652-4. PubMed ID: 12459094 [No Abstract] [Full Text] [Related]
55. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup? Kubo H; Yanai M; Azuma A Am J Respir Crit Care Med; 2013 May; 187(9):1029-30. PubMed ID: 23634865 [No Abstract] [Full Text] [Related]